ES2450592T3 - Uso de ulipristal para tratar los fibroides uterinos - Google Patents

Uso de ulipristal para tratar los fibroides uterinos Download PDF

Info

Publication number
ES2450592T3
ES2450592T3 ES09706347.3T ES09706347T ES2450592T3 ES 2450592 T3 ES2450592 T3 ES 2450592T3 ES 09706347 T ES09706347 T ES 09706347T ES 2450592 T3 ES2450592 T3 ES 2450592T3
Authority
ES
Spain
Prior art keywords
cbd
uterine fibroids
ulipristal
ulipristal acetate
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09706347.3T
Other languages
English (en)
Spanish (es)
Inventor
Erin Gainer
Lynnette Nieman
André Ulmann
Diana Blithe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire HRA Pharma SAS
United States Department of Health and Human Services
Original Assignee
Laboratoire HRA Pharma SAS
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2450592(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire HRA Pharma SAS, United States Department of Health and Human Services filed Critical Laboratoire HRA Pharma SAS
Application granted granted Critical
Publication of ES2450592T3 publication Critical patent/ES2450592T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
ES09706347.3T 2008-01-29 2009-01-28 Uso de ulipristal para tratar los fibroides uterinos Active ES2450592T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21610 2008-01-29
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Publications (1)

Publication Number Publication Date
ES2450592T3 true ES2450592T3 (es) 2014-03-25

Family

ID=40551565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09706347.3T Active ES2450592T3 (es) 2008-01-29 2009-01-28 Uso de ulipristal para tratar los fibroides uterinos

Country Status (20)

Country Link
US (5) US8299050B2 (cg-RX-API-DMAC10.html)
EP (2) EP2252301B1 (cg-RX-API-DMAC10.html)
JP (2) JP5906016B2 (cg-RX-API-DMAC10.html)
KR (2) KR101571400B1 (cg-RX-API-DMAC10.html)
AU (1) AU2009209652B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0907028B8 (cg-RX-API-DMAC10.html)
CA (2) CA2857798A1 (cg-RX-API-DMAC10.html)
CY (1) CY1116485T1 (cg-RX-API-DMAC10.html)
DK (1) DK2252301T3 (cg-RX-API-DMAC10.html)
ES (1) ES2450592T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20140132T1 (cg-RX-API-DMAC10.html)
IL (2) IL207182A (cg-RX-API-DMAC10.html)
MX (1) MX2010008270A (cg-RX-API-DMAC10.html)
NZ (1) NZ587439A (cg-RX-API-DMAC10.html)
PL (1) PL2252301T3 (cg-RX-API-DMAC10.html)
PT (1) PT2252301E (cg-RX-API-DMAC10.html)
SI (1) SI2252301T1 (cg-RX-API-DMAC10.html)
TW (1) TWI445537B (cg-RX-API-DMAC10.html)
WO (1) WO2009095418A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201006049B (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
MX2012010327A (es) * 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
JP6200493B2 (ja) * 2012-09-28 2017-09-20 あすか製薬株式会社 無定形ウリプリスタール酢酸エステル
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
US20150320766A1 (en) * 2012-12-14 2015-11-12 Laboratoire Hra-Pharma Copper intrauterine device
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
KR20150139919A (ko) * 2013-04-10 2015-12-14 쁘레글렘 에스아 자궁 섬유종의 치료에서 사용하기 위한 프로게스테론 수용체 조절제
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
US10238722B2 (en) 2014-11-24 2019-03-26 Ramot At Tel-Aviv University Ltd. Pigment epithelium derived factor (PEDF) for the treatment of uterine fibroids
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
WO2021166001A1 (en) 2020-02-19 2021-08-26 Velfag Ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
ATE235907T1 (de) 1995-02-02 2003-04-15 Schering Ag Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
ES2152671T3 (es) 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
AU747710B2 (en) 1997-11-14 2002-05-23 Akzo Nobel N.V. Progestogen-antiprogestogen regimens
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20090149434A1 (en) 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
JP2010514793A (ja) 2006-12-28 2010-05-06 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンのバイオアベイラビリティを改善するための方法および製剤
SI2148681T1 (sl) * 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
US9180133B2 (en) 2015-11-10
ZA201006049B (en) 2011-05-25
JP6138838B2 (ja) 2017-05-31
IL234149B (en) 2019-02-28
EP2252301A1 (en) 2010-11-24
HRP20140132T1 (hr) 2014-05-09
JP2015120711A (ja) 2015-07-02
JP5906016B2 (ja) 2016-04-20
CY1116485T1 (el) 2017-03-15
KR20110021709A (ko) 2011-03-04
TWI445537B (zh) 2014-07-21
US20140187525A1 (en) 2014-07-03
US8722653B2 (en) 2014-05-13
CA2713254A1 (en) 2009-09-06
US20090192130A1 (en) 2009-07-30
US20170246189A1 (en) 2017-08-31
KR101571400B1 (ko) 2015-11-24
NZ587439A (en) 2012-06-29
MX2010008270A (es) 2011-01-14
WO2009095418A1 (en) 2009-08-06
KR20150055626A (ko) 2015-05-21
PT2252301E (pt) 2014-02-24
US9682088B2 (en) 2017-06-20
TW200944211A (en) 2009-11-01
IL207182A0 (en) 2010-12-30
PL2252301T3 (pl) 2014-07-31
EP2684565B1 (en) 2019-10-02
BRPI0907028A2 (pt) 2015-07-07
EP2252301B1 (en) 2013-12-11
CA2713254C (en) 2014-10-07
DK2252301T3 (en) 2014-02-17
EP2684565A1 (en) 2014-01-15
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
IL207182A (en) 2015-06-30
US20130023506A1 (en) 2013-01-24
BRPI0907028B8 (pt) 2021-05-25
JP2011510949A (ja) 2011-04-07
IL234149A0 (en) 2014-09-30
AU2009209652A1 (en) 2009-08-06
BRPI0907028A8 (pt) 2019-08-13
CA2857798A1 (en) 2009-09-06
BRPI0907028B1 (pt) 2019-09-24
US8299050B2 (en) 2012-10-30
AU2009209652B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
US9682088B2 (en) Method for treating uterine fibroids
JP2011510949A5 (cg-RX-API-DMAC10.html)
BRPI1003661A2 (pt) associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
PT1443966E (pt) Método para a prevenção ou tratamento das doenças ginecológicas benignas
JP2012051920A (ja) 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用
TW201400121A (zh) 治療婦科疾病之組合物
ES2295050T3 (es) Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
Flam et al. Methotrexate treatment for retained placental tissue
US20060100155A1 (en) Method for the therapeutic management of endometriosis
Fatima et al. Spontaneous pregnancy rate after hysteroscopic removal of endometrial polyps in infertility patients; Experience at King Hussein Medical Center
Busacca Pain and endometriosis: an overview
Crauciuc et al. PREVENTION WITH DESORGESTREL OF ENDOMETRIOUS CYSTS RECURRENCE AFTER SURGICAL TREATMENT
Tsuchiya et al. Gynecology and Minimally Invasive Therapy
Sahu et al. Dysfunctional Uterine Bleeding: When to Intervene Surgically?